A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

Documenti analoghi

• Efficacy and safety of European Medicines Agency ( EMA )‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity
  di: Rocco Barazzoni, et al.
  Pubblicazione: (2025)
• Characterization of the effect of naltrexone/bupropion on body composition
  di: Vanessa Tardio, et al.
  Pubblicazione: (2025)
• Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
  di: Man Tang, et al.
  Pubblicazione: (2025)
• Meta‐analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders‐European Chapter (IFSO‐EC) guidelines on multimodal strategies for the surgical treatment of obesity
  di: Maurizio De Luca, et al.
  Pubblicazione: (2025)
• Counting the lifetime cost of obesity: Analysis based on national England data
  di: Adrian Heald, et al.
  Pubblicazione: (2024)